Penn Researchers Block GPNMB to Halt Parkinson Spread
SkimNews Take
Targeting GPNMB with antibodies suggests a new therapeutic strategy that could slow Parkinson's progression by directly inhibiting the spread of toxic proteins, rather than solely managing symptoms.
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- GPNMB is identified as a protein that helps spread Parkinson's disease pathology between neurons, as reported by University of Pennsylvania researchers in a Neuron paper.
- Microglia (brain immune cells) release GPNMB when neighboring neurons are damaged, creating a vicious cycle that accelerates neurodegeneration.
- Monoclonal antibodies targeting GPNMB halted the intercellular spread of toxic alpha‑synuclein in early laboratory experiments, indicating a possible disease‑modifying therapy.
- Alice Chen‑Plotkin, lead author and Parker Family Professor of Neurology, emphasizes that current treatments only relieve symptoms, making this discovery a promising step toward slowing disease progression.
Why it matters: Patients with early‑stage Parkinson’s gain a disease‑modifying therapy, reducing long‑term care costs and slowing the >90,000 annual U.S. diagnoses, while pharma firms see a new market for GPNMB‑targeted drugs.
